Glax­it: Flag­ging a loom­ing threat from Gilead and a weak pipeline, Neil Wood­ford is giv­ing up on GSK and pulling out

Af­ter watch­ing Glax­o­SmithK­line grow in­creas­ing­ly ham­pered by a weak pipeline and “stretched” fi­nan­cials, long­time in­vestor Neil Wood­ford has de­cid­ed to quit the phar­ma gi­ant, wor­ried that a ri­val HIV ther­a­py from Gilead may soon crip­ple Vi­iV, the phar­ma gi­ant’s one bright spot.

In a lengthy blog post to­day ti­tled Glax­it, Wood­ford not­ed that he’s been ad­vis­ing the com­pa­ny for years now to split up and do some­thing pos­i­tive for in­vestors. For­mer CEO An­drew Wit­ty, though, re­ject­ed the sug­ges­tions and new CEO Em­ma Walm­s­ley seems set on the same path.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER